Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (261)
Cancellation by sponsor (83)
Prescription medicine registration (27)
Section 14, TGO91 consent (6)
Australian public assessment report (AusPar) (1)
Prescription medicine decision summary (1)

Date

2026 (2)
2025 (23)
2024 (13)
2023 (18)
2022 (35)
2021 (68)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (17)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (5)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (2)
1998 (1)
1996 (3)
1994 (2)
1991 (5)

Search

Sponsor content

379 result(s) found, displaying 111 to 120

TEMOZOLOMIDE JUNO temozolomide 5 mg capsule bottle (354885)

28 April 2021

ARTG

Australian Register of Therapeutic Goods (ARTG) information for TEMOZOLOMIDE JUNO temozolomide 5 mg capsule bottle.
DEXAMETHASONE JUNO (Juno Pharmaceuticals Pty Ltd)

19 September 2022

Prescription medicine registration

Active ingredients: Dexamethasone sodium phosphate.
GLATIRA glatiramer acetate 20 mg/1mL solution for injection prefilled syringe (303650)

12 November 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for GLATIRA glatiramer acetate 20 mg/1mL solution for injection prefilled syringe.
GLATIRA glatiramer acetate 40 mg/1mL solution for injection prefilled syringe (303649)

12 November 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for GLATIRA glatiramer acetate 40 mg/1mL solution for injection prefilled syringe.
MULTIROS glatiramer acetate 40 mg/1mL solution for injection prefilled syringe (303648)

12 November 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for MULTIROS glatiramer acetate 40 mg/1mL solution for injection prefilled syringe.
MULTIROS glatiramer acetate 20 mg/1mL solution for injection prefilled syringe (303651)

12 November 2020

ARTG

Australian Register of Therapeutic Goods (ARTG) information for MULTIROS glatiramer acetate 20 mg/1mL solution for injection prefilled syringe.
ESMOLOL JUNO (Juno Pharmaceuticals Pty Ltd)

8 July 2022

Prescription medicine registration

Active ingredients: Esmolol hydrochloride.
PEMETREXED ACT pemetrexed (as disodium) 100mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
PEMETREXED ACT pemetrexed (as disodium) 500mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TIROSTAT tirofiban (as hydrochloride) 12.5mg/50mL Concentrated Injection for infusion Vial Cancelled under Section 30(1)(c) of the Act

28 June 2022

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Is there anything wrong with this page?

Help us improve

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.